This study demonstrates that DOTA-INER-PP-F11N-1 and DOTA-INER-PP-F11N-2 are promising CCK2R-targeted radiopharmaceuticals with improved in vivo stability, enhanced tumor uptake, and reduced renal toxicity compared with [177Lu]Lu-DOTA-PP-F11N. The gene discussed is CCKBR; the disease is neoplasm.